Liu Xiaomeng, Ge Shuping, Zhang Aijun
Department of Pediatrics, Qilu Hospital of Shandong University, Jinan 250012, China.
Department of Pediatric and Adult Congenital Cardiology, Geisinger Clinic, Danville, PA 17822, USA.
Children (Basel). 2024 Jul 22;11(7):884. doi: 10.3390/children11070884.
Anthracyclines have significantly improved the survival of children with malignant tumors, but the associated cardiotoxicity, an effect now under the purview of pediatric cardio-oncology, due to its cumulative and irreversible effects on the heart, limits their clinical application. A systematic screening and risk stratification approach provides the opportunity for early identification and intervention to mitigate, reverse, or prevent myocardial injury, remodeling, and dysfunction associated with anthracyclines. This review summarizes the risk factors, surveillance indexes, and preventive strategies of anthracycline-related cardiotoxicity to improve the safety and efficacy of anthracyclines.
蒽环类药物显著提高了患有恶性肿瘤儿童的生存率，但由于其对心脏具有累积性和不可逆的影响，与之相关的心脏毒性（这一效应目前属于儿科心脏肿瘤学的范畴）限制了它们的临床应用。系统的筛查和风险分层方法为早期识别和干预提供了机会，以减轻、逆转或预防与蒽环类药物相关的心肌损伤、重塑和功能障碍。本综述总结了蒽环类药物相关心脏毒性的危险因素、监测指标和预防策略，以提高蒽环类药物的安全性和有效性。
